S501
Clinical - Haemotology
ESTRO 2026
The median follow-up for all patients was 46 months (2–153 months). There were 16 MF-related deaths (SD: 10/19, LD: 6/28) and 7 deaths due to other causes. From the initial TSEI application, the 5-year DFS was 42.1% for the SD group and 72.2% for the LD group (p > 0.05). The OS was 50.1% for the SD group and 75% for the LD group (p > 0.05). Conclusion: TSEI is an effective therapeutic option for MF across all disease stages, providing high response and substantial symptom relief. However, remissions are typically transient, with most relapses occurring within one-year. While SD-TSEI (36 Gy) achieves high CR rates, it is associated with significant acute skin toxicity, extended hospitalization, and may restrict the feasibility of subsequent re-irradiation. In contrast, LD- TSEI (12 Gy), administered in repeatable courses until an adequate response is attained, offers comparable survival outcomes with reduced toxicity and enhanced patient comfort. Due to its favorable safety profile, convenience, and potential for re-treatment, LD-TSEI has become the preferred regimen at our institution. Keywords: mycosis fungoides, TSEI Quality of Life After Total Skin Electron Beam Irradiation in patients with Mycosis Fungoides: A Prospective Study from a National Reference Center Peppa Abelairas Ramos, Jesús Romero Fernández, Irma Zapata Paz, Beatriz Gil Haro, Raquel Benlloch Rodríguez, María Ángeles Ruiz Rodriguez, Irene Ávila Gómez, Clara Caballero Valls, Susana Sánchez Rico, Sofía Santana Jiménez, Marta López Valcárcel, María Hernández De Miguel, Cristina de la Fuente Alonso, Sofía Córdoba Largo, Joaquin Velasco Jiménez, Maria Isabel García Berrocal Radiation Oncology, Puerta de hierro University Hospital, Madrid, Spain Purpose/Objective: Cutaneous T-cell lymphomas (CTCLs) are malignant lymphoproliferative disorders characterized by clonal proliferation of T lymphocytes that infiltrate the skin. They account for approximately 75–80% of all primary cutaneous lymphomas, with mycosis fungoides (MF) being the most common subtype, representing around 60% of all CTCLs. The disease primarily involves the skin and typically follows a slow Digital Poster Highlight 658 progression. Total skin electron beam therapy (TSEB) is an effective local treatment that can be used at any stage of MF.Objectives: To analyze tumor response, toxicity, and quality of life (QoL) in patients with MF treated with TSEB at a national reference center. Material/Methods:
Induced Lymphopenia: A Retrospective Study and Literature Review. Adv Radiat Oncol. 2021 Jul 29;6(6):100761. Keywords: radiotherapy alone, spleen dose, lymphopenia
Digital Poster 327
Total Skin Electron Beam Irradiation in Mycosis Fungoides: Low-Dose Regimen as the Preferred Approach Over High-Dose Irradiation Yavuz Anacak 1 , Tugce Bozkurt Vardarli 1 , Ayda Acar 2 , Gulfiye Selin Izgi 2 , Nima Ghahramani 1 , Serra Kamer 1 , Ilgen Ertam Sagduyu 2 1 Radiation Oncology, Ege University, Izmir, Turkey. 2 Dermatology, Ege University, Izmir, Turkey Purpose/Objective: Radiotherapy is an effective treatment for Mycosis Fungoides (MF), with total skin electron irradiation (TSEI) commonly used in advanced stages. This study compares the effectiveness of low-dose (LD) 12 Gy vs. standard-dose (SD) 30 Gy TSEI. Material/Methods: Between 2011-2025, 47 patients with MF underwent TSEI utilizing a modified Stanford Technique. TSEI was performed employing six fields and dual gantry angles, with daily fractions of 1–1.2 Gy. Until 2016, 19 patients received SD-TSEI at 36 Gy, from 2017 to 2025, 28 were treated with a reduced dose of 12 Gy (LD-TSEI). 14 patients underwent a second course of TSEI, and three received a third course due to inadequate response or relapse/progression following the initial treatment series, 15 of 17 those re-irradiated were at the SD-TSEI group. Median age of the cohort was 57 years (31–88), comprising 13 females and 34 males. According to the TNMB staging system, 2 patients (4.3%) were stage-I, 22 (46.8%) stage-II, 14 (29.8%) stage-III, and 9 (19.1%) stage-IV.
Results: In the SD group, 15 patients achieved complete response (CR) and 4 experienced partial response (PR). In the LD group, 20 achieved CR, while 8 achieved PR. Relapse occurred in 17 patients from the HD group and 21 patients from the LD group. Mean time to relapse was 13 months (1–103 months), with 14.8 months for the HD and 11.6 months for the LD group.
Made with FlippingBook - Share PDF online